Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 8-K (Current Report)
Date of Report: February 23, 2026
Principal Executive Offices: Boca Raton, Florida
The filing reports a corporate event under Item 8.01 (Other Events). The Company announced it will host a webinar on February 27, 2026, at 9:30 a.m. ET regarding the registrational pathway of its candidate drug, XPro1595 (XPro™), for the treatment of early Alzheimer's disease.
Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing is limited to the announcement of a corporate event and the inclusion of a press release as an exhibit.
Material Changes
No material financial changes or operational metrics are reported in this filing. The only reported event is the scheduled webinar concerning the development status of XPro1595.
Guidance, Outlook, and Risks
Management Commentary: The Company is providing an update on the registrational pathway for XPro1595 via a webinar. No specific clinical trial results, regulatory decisions, or financial guidance are detailed in the text of this 8-K.
Risks and Contingencies: The filing text does not explicitly list new risks or contingencies beyond the inherent uncertainties of the drug development process implied by the webinar topic.
Key Facts for Investor Verification
- Verify the date and time of the upcoming webinar: February 27, 2026, at 9:30 a.m. ET.
- Review the attached press release (Exhibit 99.1) for specific details on the registrational pathway of XPro1595.
- Confirm the current development status of XPro1595 for early Alzheimer's disease through the webinar materials.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial metrics.